These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21504254)

  • 1. Safety of long-term bisphosphonate therapy for the management of osteoporosis.
    Lewiecki EM
    Drugs; 2011 Apr; 71(6):791-814. PubMed ID: 21504254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and potential risks of bisphosphonate therapy A narrative review.
    El Osta L; El Osta N; El Osta H
    J Med Liban; 2016; 64(4):228-37. PubMed ID: 29845849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S; Bilezikian JP; Dempster DW; Lewiecki EM; Miller PD; Neer RM; Recker RR; Shane E; Shoback D; Potts JT
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the treatment of osteoporosis.
    Diab DL; Watts NB
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate-associated adverse events.
    Papapetrou PD
    Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.
    Baillargeon J; Kuo YF; Lin YL; Wilkinson GS; Goodwin JS
    Ann Pharmacother; 2011 Oct; 45(10):1199-206. PubMed ID: 21954448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and Benefits of Bisphosphonate Therapies.
    Reyes C; Hitz M; Prieto-Alhambra D; Abrahamsen B
    J Cell Biochem; 2016 Jan; 117(1):20-8. PubMed ID: 26096687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bisphosphonates: risks and benefits of long term use.
    Hermann AP; Abrahamsen B
    Curr Opin Pharmacol; 2013 Jun; 13(3):435-9. PubMed ID: 23434194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risks of bisphosphonate therapy.
    Watts NB
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):523-9. PubMed ID: 25166043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review.
    Thorsteinsson AL; Vestergaard P; Eiken P
    Osteoporos Int; 2014 Jul; 25(7):1937-44. PubMed ID: 24664275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety issues with bisphosphonate therapy for osteoporosis.
    Suresh E; Pazianas M; Abrahamsen B
    Rheumatology (Oxford); 2014 Jan; 53(1):19-31. PubMed ID: 23838024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.
    Reid IR
    Skeletal Radiol; 2011 Sep; 40(9):1191-6. PubMed ID: 21847749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Brown JP; Morin S; Leslie W; Papaioannou A; Cheung AM; Davison KS; Goltzman D; Hanley DA; Hodsman A; Josse R; Jovaisas A; Juby A; Kaiser S; Karaplis A; Kendler D; Khan A; Ngui D; Olszynski W; Ste-Marie LG; Adachi J
    Can Fam Physician; 2014 Apr; 60(4):324-33. PubMed ID: 24733321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
    Rizzoli R; Akesson K; Bouxsein M; Kanis JA; Napoli N; Papapoulos S; Reginster JY; Cooper C
    Osteoporos Int; 2011 Feb; 22(2):373-90. PubMed ID: 21085935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.